Press review archive
2019 – February 28
ITFPHARMA
ITF Pharma has been named an honoree for the 2018 Patient Impact Award, presented by Life Sciences Pennsylvania, for the successful launch and approval of TIGLUTIK
2018 – September 06
ITFPHARMA
ITF PHARMA announces FDA approval of TIGLUTIK™ (riluzole) oral suspension for the tratment of amyotrophic lateral sclerosis (ALS)